Journal article
A real‐world, observational study of erenumab for migraine prevention in Canadian patients
Abstract
OBJECTIVES: To assess real-world effectiveness, safety, and usage of erenumab in Canadian patients with episodic and chronic migraine with prior ineffective prophylactic treatments.
BACKGROUND: In randomized controlled trials, erenumab demonstrated efficacy for migraine prevention in patients with ≤4 prior ineffective prophylactic migraine therapies. The "Migraine prevention with AimoviG: Informative Canadian real-world study" (MAGIC) assessed …
Authors
Becker WJ; Spacey S; Leroux E; Giammarco R; Gladstone J; Christie S; Akaberi A; Power GS; Minhas JK; Mancini J
Journal
Headache The Journal of Head and Face Pain, Vol. 62, No. 4, pp. 522–529
Publisher
Wiley
Publication Date
April 2022
DOI
10.1111/head.14291
ISSN
0017-8748